497P - Triple negative breast cancer and androgen receptor expression: a forerunner for a novel hormonal approach

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Breast Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Prameela Chelakkot G
Citation Annals of Oncology (2015) 26 (suppl_9): 153-155. 10.1093/annonc/mdv534
Authors P. Chelakkot G1, R. Ravind2, S.N. Vijayan3, S. K4, S. V S5, K. Pavithran6
  • 1Associate Professor, Department Of Radiation Oncology, Amrita Institute of Medical Sciences, 682041 - Kochi/IN
  • 2Radiation Oncology, HCG Bangalore Institute of Oncology Speciality Centre, Bangalore/IN
  • 3Department Of Pathology, Amrita Institute of Medical Sciences, 682041 - Kochi/IN
  • 4Radiation Oncology, Amrita Institute of Medical Sciences, 682041 - Kochi/IN
  • 5Department Of Biostatistics, Amrita Institute of Medical Sciences, 682041 - Kochi/IN
  • 6Department Of Medical Oncology, Amrita Institute of Medical Sciences, 682041 - Kochi/IN



About 15%-20% of breast cancer is triple negative (TNBC), which carries a poor prognosis. Target molecules investigated in TNBC are, PARP (poly-ADP-ribose polymerase) inhibitor, EGFR (epidermal growth factor receptor) inhibitor and also androgen receptor.


Details of TNBC patients, with follow up till 2011; and retrievable pathological slides and blocks, were analysed for AR status. Slides were reviewed for AR status using Androgen receptor Monoclonal (F39.4.1clone) Mouse antibodies. Slides were de-paraffinised and hydrated. Antigen was heat-retrieved. Horse-radish-peroxidase was used with diamine-benzaldehyde for antibody detection. Androgen receptor positivity was read as percentage and intensity of nuclear staining. Nuclear expression >10% was taken as nuclear positive. All slides were interpreted by a single breast-onco-pathologist.


Of the TNBC patients who had follow up, 72 slides were reviewed for AR status. Three had nuclear AR expression and six had cytoplasmic expression. Mean follow up was 52.53 months. Five year PFS for AR negative was 80.41% and for AR positive 75%. Median PFS was 19.93 months. Cytoplasmic positive group were disease free at the end of follow up. Pre-menopausal, AR positive had five year PFS of 83.3%. Post-menopausal group had median PFS of 19.93 months. Higher grade had less AR expression. Node positive had 5 year PFS of 60%.


AR expression was seen in elderly, post-menopausal, node-positive group as claimed by MacGhan, and Lou et al. AR-positive patients had poor progression-free interval. Luminal androgen receptor (LAR) sub-type of TNBC is identified to have decreased relapse-free-survival and is believed to have AR signaling. Luminal androgen receptor sub-set, encompassing a poor-prognostic group, might be more sensitive to anti-androgen molecules, and can be the sub-set for targeted tailored treatment options, improving the poor outcomes.

Clinical trial identification


All authors have declared no conflicts of interest.